0001264124-12-000183.txt : 20120810 0001264124-12-000183.hdr.sgml : 20120810 20120810183501 ACCESSION NUMBER: 0001264124-12-000183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120808 FILED AS OF DATE: 20120810 DATE AS OF CHANGE: 20120810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Costa Paulo F CENTRAL INDEX KEY: 0001465928 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 121025595 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2012-08-08 1 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001465928 Costa Paulo F 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 1 0 0 0 Common Stock 2012-08-08 4 J 0 24933.0 31.0 D 1067.0 D Common Stock 2012-08-08 4 J 0 1067.0 31.0 D 0.0 D Non-Qualified Stock Option (right to buy) 11.26 2012-08-08 4 J 0 30000.0 31.0 D 2016-06-09 Common Stock 30000.0 0.0 D Non-Qualified Stock Option (right to buy) 13.18 2012-08-08 4 J 0 20000.0 31.0 D 2018-05-24 Common Stock 20000.0 0.0 D Non-Qualified Stock Option (right to buy) 21.52 2012-08-08 4 J 0 20000.0 31.0 D 2017-04-29 Common Stock 20000.0 0.0 D Non-Qualified Stock Option (right to buy) 27.3 2012-08-08 4 J 0 20000.0 31.0 D 2019-05-15 Common Stock 20000.0 0.0 D Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Includes 3,000 unvested restricted stock units that were cancelled at the effective time of the merger pursuant to the merger agreement in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit. Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these options, whether or not vested, were fully vested immediately prior to and cancelled at the effective time of the merger in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option. By: /s/ James R Oehler, Attorney-in-Fact For: Paulo F Costa 2012-08-10